Effects of Ginkgo biloba extract on cytokines in rats with TNBS-induced ulcerative colitis

World Chinese Journal of Digestology

Volumn 12, Issue 2, 2004, Pages 371-375

  Zhou, Yan Hong ^a   Yu, Jie Ping ^a   He, Xiao Fei ^b,c   Yu, Xi Qiu ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Xianning Medical College   (China)

^c Xianning Medical College   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GINKGO BILOBA EXTRACT; INTERLEUKIN 12; INTERLEUKIN 4; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GINKGO BILOBA; HISTOLOGY; NONHUMAN; RAT; SCORING SYSTEM; SERUM; SPLEEN CELL; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS;

EID: 1942537886     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v12.i2.371     Document Type: Article

References (36)

1. Gui HF, Jiang XL. Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heprin. World J Gastroenterol 1999;5:448-450
2. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol 2002;8:158-161
3. Lehmann FS. Pathophysiology of inflammatory bowel disease. Ther Umsch 2003;60:127-132
4. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical consideration. Gastroenterology 1994;106: 533-539
5. Stevceva L. Cytokines and their antagonists as therapeutic agents. Curr Med Chem 2002;9:2201-2207
6. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-533
7. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998;22:382-389
8. Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curr Pharm Des 2003;9:1107-1113
9. Ardizzone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med 2002; 252:475-496
10. Wu HG, Zhou LB, Pan YY, Huang C, Chen HP, Shi Z, Hua XG. Study of the mechanisms of acupuncture and moxibustion treatment for ulcerative colitis rats in view of the gene expression of cytokines. World J Castroenterol 1999;5:515-517
11. Zheng L, Gao ZQ, Wang SX. A chronic ulcerative colitis model in rats. World J Gastroenterol 2000;6:150-152
12. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SG, Van Rees EP. Chromic experimental colitis induced by dextran sulphate sodium(DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998;114:385-391
13. Zhu F, Qian J, Pan G. The establishment of TNBS-induced experimental colitis. Zhongguo Yixue Kexueyuan Xuebao 1998; 20:271-278
14. Crabtree JE, Shallcross TM, Heatley RV, Wyatt JI. Mucosal tumour necrosis facter α and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991;32:1473-1477
15. Bridi R, Crossetti FP, Steffen VM, Henriques AT. The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats. Phytother Res 2001;15:449-451
16. Shen J, Wang J, Zhao B, Hou J, Gao T, Xin W. Effects of EGb 761 on nitric oxide and oxygen free radicals, myocardial damage and arrhythmia in ischemia-reperfusion injury in vivo. Biochim Biophys Acta 1998;1406:228-236
17. Lee EJ, Chen HY, Wu TS, Chen TY, Ayoub IA, Maynard KI. Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in: Sprague-Dawley Rats. J Neurosci Res 2002;68:636-645
18. Itil TM, Eralp E, Tsambis E, Itil KZ, Stein U. Central nervous system effects of ginkgo biloba, a plant extract. Am J Ther 1996;3:63-73
19. Monteleone G, MacDonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease. Ann Med 2000;32:552-560
20. Anand AC, Adya CM. Cytokines and inflammatory bowel disease. Trop Gastroenterol 1999;20:97-106
21. Dohi T, Fujihashi K, Kiyono H, Elson CO, McGhee JR. Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis. Gastroenterology 2000;119:724-733
22. Romagnani S. Th1/Th2 Cells. Inflamm Bowel Dis 1999;5:285-294
23. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999;11:648-656
24. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, Maggi E, Pupilli C, Tonelli F, Romagnani S. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997;150:823-832
25. Klein W, Tromm A, Griga T, Fricke H, Folwaczny C, Hocke M, Eitner K, Marx M, Duerig N, Epplen JT. Interleukin-4 and interleukin-4 receptor gene polymorphisms in inflammatory bowel diseases. Genes Immun 2001;2:287-289
26. Fort M, Lesley R, Davidson N, Menon S, Brombacher F, Leach M, Rennick D. IL-4 exacerbates disease in a Th1 cell transfer model of colitis. J Immunol 2001;166:2793-2800
27. Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis 1998;4:285-290
28. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: A murine model of T helper cell type 2 Colitis treatable with antibodies to interleukin 4. J Exp Med 1998;188:1929-1939
29. Tozawa K, Hanai H, Sugimoto K, Baba S, Sugimura H, Aoshi T, Uchijima M, Nagata T, Koide Y. Evidence for the critical role of interleukin-12 but not interferon-gamma in the pathogenesis of experimental colitis in mice. J Gastroenterol Hepatol 2003;18:578-587
30. Schmidt C, Marth T, Wittig BM, Hombach A, Abken H, Stallmach A. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology 2002;70: 177-183
31. Spencer DM, Veldman GM, Banerjee S, Willis J, Levine AD. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002;122:94-105